Janane 2014.

Study characteristics
Methods	Study design: placebo controlled RCT Number of centers/setting: presumed single center/not reported Country: Morocco Dates of the study: January 2008 to December 2012
Participants	Total number of participants randomized: 356 tamsulosin group: 186 placebo group: 170 Age (mean, years): tamsulosin group: 41.2 (SD 12.4) placebo group: 43.4 (SD 12.2) Sex (M/F): tamsulosin group: 108/78 placebo group: 104/66 Stone location: tamsulosin group: 30 upper calyces/23 mid‐calyces/79 renal pelvis/54 lumbar ureter placebo group: 26 upper calyces/19 mid‐calyces/75 renal pelvis/50 lumbar ureter Stone size (mean, mm): tamsulosin group: 9.2 (SD 2.8) placebo group: 9.2 (SD 3) Inclusion criteria: people with lower ureteral stones undergoing ESWL Exclusion criteria: UTI, multiple stones, severe hydronephrosis, solitary kidney, congenital urinary anomalies or previous ureteral surgery, severe obesity, pregnancy, lactation or previous treatment with alpha‐blockers
Interventions	Treatment group: tamsulosin 0.4 mg/day for max 2 weeks or until an alternative treatment was applied standard care: diclofenac 25 mg 3 times daily, recommended drink minimum 2 L water daily Control group: placebo SWL: Lithotriptor: Storz medical lithotripter (MODULITH° SLX‐F2) Power setting: not reported, interval: not reported Number of shocks: not reported, number of sessions: 1
Outcomes	Stone free rate, stone expulsion time, ureteral colic How measured: abdominal ultrasound or IVP; CT Time point measured: weekly, 3 months Subgroups: stone size
Funding sources	Not reported
Declarations of interest	None
Notes	Language of publication: English Type of publication: full text Date of contact attempt with study authors: none Contact status: N/A
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "simple random allocation." Comment: method of random sequence generation unclear.
Allocation concealment (selection bias)	Unclear risk	Quote: "simple random allocation." Comment: allocation concealment not addressed.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "placebo‐controlled medical treatment." Comment: no additional information provided to support that participants were adequately blinded.
Blinding of outcome assessment (detection bias) Investigator assessed; susceptible (stone clearance, time to stone clearance)	Unclear risk	Comment: blinding of outcome assessors not addressed.
Blinding of outcome assessment (detection bias) Investigator assessed; susceptible (major adverse events)	Unclear risk	Comment: blinding of outcome assessors not addressed.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: unable to assess what proportion of randomized participants were included in outcome analyses.
Selective reporting (reporting bias)	Unclear risk	Comment: no protocol available.
Other bias (additional SWL sessions)	Low risk	Quote: "after single ESWL session…" Comment: single SWL session.